Prior oral contraceptive use in ovarian cancer patients: Assessing associations with overall and progression-free survival

Aminah Jatoi, Nathan R. Foster, Kimberly R. Kalli, Robert A. Vierkant, Zhiying Zhang, Melissa C. Larson, Brooke Fridley, Ellen L Goode

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Prior studies have described a reduced risk of developing ovarian cancer with the use of oral contraceptives. In this context, we decided to examine if oral contraceptive use prior to a diagnosis of ovarian cancer is associated with better overall and progression-free survival. Methods: This retrospective cohort study included ovarian cancer patients who were seen at the Mayo Clinic in Rochester, Minnesota from 2000 through 2013. Patients completed a risk factor questionnaire about previous oral contraceptive use, and clinical data were extracted from the electronic medical record. Results: A total of 1398 ovarian cancer patients responded to questions on oral contraceptive use; 571 reported no prior use with all others having responded affirmatively to oral contraceptive use. Univariate analyses found that oral contraceptive use (for example, ever versus never) was associated with better overall survival (hazard ratio (HR) 0.73 (95 % confidence interval (CI): 0.62, 0.86); p = 0.0002) and better progression-free survival (HR 0.71 (95 % CI: 0.61, 0.83); p <0.0001). In multivariate analyses, contraceptive use continued to yield a favorable, statistically significant association with progression-free survival, but such was not the case with overall survival. Conclusions: This study suggests that previous oral contraceptive use is associated with improved progression-free survival in patients diagnosed with ovarian cancer.

Original languageEnglish (US)
Article number711
JournalBMC Cancer
Volume15
Issue number1
DOIs
StatePublished - Oct 15 2015

Fingerprint

Oral Contraceptives
Ovarian Neoplasms
Disease-Free Survival
Confidence Intervals
Survival
Electronic Health Records
Contraceptive Agents
Cohort Studies
Multivariate Analysis
Retrospective Studies

Keywords

  • Oral contraceptives
  • Ovarian cancer
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Prior oral contraceptive use in ovarian cancer patients : Assessing associations with overall and progression-free survival. / Jatoi, Aminah; Foster, Nathan R.; Kalli, Kimberly R.; Vierkant, Robert A.; Zhang, Zhiying; Larson, Melissa C.; Fridley, Brooke; Goode, Ellen L.

In: BMC Cancer, Vol. 15, No. 1, 711, 15.10.2015.

Research output: Contribution to journalArticle

Jatoi, Aminah ; Foster, Nathan R. ; Kalli, Kimberly R. ; Vierkant, Robert A. ; Zhang, Zhiying ; Larson, Melissa C. ; Fridley, Brooke ; Goode, Ellen L. / Prior oral contraceptive use in ovarian cancer patients : Assessing associations with overall and progression-free survival. In: BMC Cancer. 2015 ; Vol. 15, No. 1.
@article{ad38dbc62a6c418fbe4dc8af3486b472,
title = "Prior oral contraceptive use in ovarian cancer patients: Assessing associations with overall and progression-free survival",
abstract = "Background: Prior studies have described a reduced risk of developing ovarian cancer with the use of oral contraceptives. In this context, we decided to examine if oral contraceptive use prior to a diagnosis of ovarian cancer is associated with better overall and progression-free survival. Methods: This retrospective cohort study included ovarian cancer patients who were seen at the Mayo Clinic in Rochester, Minnesota from 2000 through 2013. Patients completed a risk factor questionnaire about previous oral contraceptive use, and clinical data were extracted from the electronic medical record. Results: A total of 1398 ovarian cancer patients responded to questions on oral contraceptive use; 571 reported no prior use with all others having responded affirmatively to oral contraceptive use. Univariate analyses found that oral contraceptive use (for example, ever versus never) was associated with better overall survival (hazard ratio (HR) 0.73 (95 {\%} confidence interval (CI): 0.62, 0.86); p = 0.0002) and better progression-free survival (HR 0.71 (95 {\%} CI: 0.61, 0.83); p <0.0001). In multivariate analyses, contraceptive use continued to yield a favorable, statistically significant association with progression-free survival, but such was not the case with overall survival. Conclusions: This study suggests that previous oral contraceptive use is associated with improved progression-free survival in patients diagnosed with ovarian cancer.",
keywords = "Oral contraceptives, Ovarian cancer, Survival",
author = "Aminah Jatoi and Foster, {Nathan R.} and Kalli, {Kimberly R.} and Vierkant, {Robert A.} and Zhiying Zhang and Larson, {Melissa C.} and Brooke Fridley and Goode, {Ellen L}",
year = "2015",
month = "10",
day = "15",
doi = "10.1186/s12885-015-1774-z",
language = "English (US)",
volume = "15",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Prior oral contraceptive use in ovarian cancer patients

T2 - Assessing associations with overall and progression-free survival

AU - Jatoi, Aminah

AU - Foster, Nathan R.

AU - Kalli, Kimberly R.

AU - Vierkant, Robert A.

AU - Zhang, Zhiying

AU - Larson, Melissa C.

AU - Fridley, Brooke

AU - Goode, Ellen L

PY - 2015/10/15

Y1 - 2015/10/15

N2 - Background: Prior studies have described a reduced risk of developing ovarian cancer with the use of oral contraceptives. In this context, we decided to examine if oral contraceptive use prior to a diagnosis of ovarian cancer is associated with better overall and progression-free survival. Methods: This retrospective cohort study included ovarian cancer patients who were seen at the Mayo Clinic in Rochester, Minnesota from 2000 through 2013. Patients completed a risk factor questionnaire about previous oral contraceptive use, and clinical data were extracted from the electronic medical record. Results: A total of 1398 ovarian cancer patients responded to questions on oral contraceptive use; 571 reported no prior use with all others having responded affirmatively to oral contraceptive use. Univariate analyses found that oral contraceptive use (for example, ever versus never) was associated with better overall survival (hazard ratio (HR) 0.73 (95 % confidence interval (CI): 0.62, 0.86); p = 0.0002) and better progression-free survival (HR 0.71 (95 % CI: 0.61, 0.83); p <0.0001). In multivariate analyses, contraceptive use continued to yield a favorable, statistically significant association with progression-free survival, but such was not the case with overall survival. Conclusions: This study suggests that previous oral contraceptive use is associated with improved progression-free survival in patients diagnosed with ovarian cancer.

AB - Background: Prior studies have described a reduced risk of developing ovarian cancer with the use of oral contraceptives. In this context, we decided to examine if oral contraceptive use prior to a diagnosis of ovarian cancer is associated with better overall and progression-free survival. Methods: This retrospective cohort study included ovarian cancer patients who were seen at the Mayo Clinic in Rochester, Minnesota from 2000 through 2013. Patients completed a risk factor questionnaire about previous oral contraceptive use, and clinical data were extracted from the electronic medical record. Results: A total of 1398 ovarian cancer patients responded to questions on oral contraceptive use; 571 reported no prior use with all others having responded affirmatively to oral contraceptive use. Univariate analyses found that oral contraceptive use (for example, ever versus never) was associated with better overall survival (hazard ratio (HR) 0.73 (95 % confidence interval (CI): 0.62, 0.86); p = 0.0002) and better progression-free survival (HR 0.71 (95 % CI: 0.61, 0.83); p <0.0001). In multivariate analyses, contraceptive use continued to yield a favorable, statistically significant association with progression-free survival, but such was not the case with overall survival. Conclusions: This study suggests that previous oral contraceptive use is associated with improved progression-free survival in patients diagnosed with ovarian cancer.

KW - Oral contraceptives

KW - Ovarian cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84944875084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944875084&partnerID=8YFLogxK

U2 - 10.1186/s12885-015-1774-z

DO - 10.1186/s12885-015-1774-z

M3 - Article

C2 - 26471496

AN - SCOPUS:84944875084

VL - 15

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 711

ER -